UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
January
22, 2007
Date
of
Report (Date of earliest event reported)
TAPIMMUNE
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-27239
|
88-0277072
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
Unit
2 - 3590 West 41st
Avenue,
Vancouver,
British Columbia, Canada
|
V6N
3E6
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(604)
264-8274
Registrant’s
telephone number, including area code
TapImmune
Inc.
202-3590
West 41st
Ave, Vancouver, British Columbia, Canada, V6N 3E6
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the
filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
__________
SECTION
8 - OTHER EVENTS
|
Item
8.01
|
Other
Events
|
In
further reference to the Company’s previous Form 8-K dated December 5, 2007, the
Company received a Notice of Allowance from the U.S. Patent and Trademark
Office, dated January 11, 2008, in connection with its U.S. Patent Appln. No.
10/046,542, entitled “Method of Enhancing an Immune Response,” which has allowed
claims that relate to methods for enhancing the cytotoxic T-lymphocyte response
to tumor cells by introducing the transporters associated with antigen
processing (“TAP”) molecule into the infected cell. U.S. Patent Appln No.
10/046,542 is considered a key patent application for the Company, as it
describes a preferable delivery method for the TAP gene sequences and serves
as
the basis for further expansion of the Company’s technology.
SECTION
9 - FINANCIAL STATEMENTS AND EXHIBITS
Item
9.01 Financial
Statements and Exhibits.
(a) Financial
statements of business acquired.
Not
applicable.
(b) Pro
forma
financial information.
Not
applicable.
(c) Shell
company transactions.
Not
applicable.
(d) Exhibits.
Not
applicable.
Investors
are cautioned that trading in the securities of the Company should be considered
highly speculative. No exchange, over-the-counter market or regulatory authority
has in any way either approved or disapproved of the contents of this Current
Report.
__________
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
TAPIMMUNE
INC.
|
||
| |
|
|
| Date: January 22, 2008 | By: | /s/ Denis Corin |
|
Denis Corin |
||
|
President,
Chief Executive Officer and Principal Executive
Officer
|
||
__________